Puma Biotechnology (PBYI) Depreciation & Amortization (CF) (2011 - 2026)

Puma Biotechnology (PBYI) has 16 years of Depreciation & Amortization (CF) data on file, last reported at $2.6 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 7.58% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 million (down 6.1% YoY) and the FY2025 annual result came in at $10.9 million, down 5.09% from the prior year.
• Depreciation & Amortization (CF) slipped to $2.6 million in Q1 2026, from $2.7 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.9 million in Q2 2024 to a low of $2.5 million in Q4 2022.
• A 5-year average of $2.7 million and a median of $2.8 million in 2025 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) dropped 17.63% — and 2023, when it rose 17.77%.
• Tracing PBYI's Depreciation & Amortization (CF) over 5 years: stood at $2.5 million in 2022, then climbed by 17.77% to $2.9 million in 2023, then slipped by 1.66% to $2.8 million in 2024, then decreased by 6.48% to $2.7 million in 2025, then retreated by 2.75% to $2.6 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $2.6 million (Q1 2026), $2.7 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.